Hematology
Expanding Horizons: The Present and Future of Bispecific Antibodies Across Oncology
Experts explore the latest bispecific antibody approvals and clinical applications, discuss barriers in community oncology, address management of cytokine release syndrome, and consider how these therapies can expand patient access to care.
Reducing Polycythemia Vera–Associated Thrombotic Risk Through Iron Regulation
Optimizing Patient Selection for CAR T, Bispecifics Mitigates Adverse Events in High-Risk MM
Understanding Hematocrit Thresholds in Polycythemia Vera Treatment
Gene Editing for Safer CAR T-Cell Therapy in Large B-Cell Lymphoma
Overcoming Delays in CAR T for Large B-Cell Lymphoma
Managing Polycythemia Vera to Reduce Risks and Improve Lives
Cost-Effectiveness Strategies Vital for Streamlining Care in Hematologic Malignancies
Optimizing Approaches to CAR T, Bispecific Therapies in Myeloma and Lymphoma
Allogeneic vs Autologous CAR T-Cell Therapy Explained
Geographic Barriers Impede Access to Novel Cancer Treatments
Managed Care Cast Presents: Challenges of Diagnosing and Managing PNH
Podcast: This Week in Managed Care—Pushback on Proposed Payment Rules and Other Health News
Podcast: This Week in Managed Care—Insurance Coverage Gains Reverse and Other Health News
Podcast: This Week in Managed Care—Verma on Health Data and Other Health News
Podcast: This Week in Managed Care—CAR T Treatments and Other Health News
Five Years of Reducing Overuse of Medical Services With Choosing Wisely
More News
FDA Approves Brentuximab Vedotin, Lenalidomide, Rituximab Triplet for R/R LBCL
Treosulfan Regimen Approved for Allo-HSCT Conditioning in AML/MDS
